Genetic Signatures (ASX: GSS) — Company Overview, News & Financial Data
Genetic Signatures is a molecular diagnostics company specializing in the development and commercialization of proprietary sample processing methods and real-time PCR screening assays.
Genetic Signatures
Genetic Signatures is a molecular diagnostics company specializing in the development and commercialization of proprietary sample processing methods and real-time PCR screening assays. The company designs and manufactures diagnostic product lines for the routine detection of infectious diseases, including gastrointestinal, respiratory, sexual health, antimicrobial resistance, meningitis, and tropical disease targets. Utilizing a proprietary base-conversion technology that simplifies nucleic acid target sequences, its diagnostic solutions enable hospital and pathology laboratories to perform rapid, high-throughput multiplex screening for a wide range of human pathogens.
Snapshot
Operations
Products and/or services of Genetic Signatures
- Gastrointestinal Diagnostic Kits: Real-time PCR screening assays designed for the multiplexed identification of bacterial, viral, and parasitic intestinal pathogens, enabling hospital and clinical pathology laboratories to detect multiple target organisms simultaneously within patient stool samples.
- Respiratory Diagnostic Assays: Multiplexed molecular assays engineered for routine clinical screening of viral and bacterial respiratory pathogens, including influenza, SARS-CoV-2, atypical pneumonia agents, and seasonal coronavirus strains across clinical and reference laboratory settings.
- Base-Conversion Nucleic Acid Technology: Proprietary molecular processing method that chemically modifies genomic DNA and RNA targets to simplify sequence complexity, enhancing target binding efficiency and improving broad-spectrum pathogen detection capabilities across clinical screening applications.
- Sexual Health and Antimicrobial Resistance Panels: Multiplex real-time PCR screening assays designed for the rapid detection of sexually transmitted infections, reproductive health pathogens, and critical antimicrobial resistance markers, including extended-spectrum beta-lactamase and carbapenemase-producing bacterial organisms in clinical specimens.
- Automated Sample Extraction and Workflow Systems: Specialized nucleic acid extraction reagents and automated sample preparation instruments designed to streamline clinical laboratory workflows, minimize hands-on operator time, and optimize high-throughput processing for downstream molecular diagnostic testing.
- Meningitis and Vector-Borne Pathogen Assays: Specialist diagnostic multiplex PCR panels designed for the rapid identification of viral, bacterial, and fungal central nervous system pathogens, alongside vector-borne tropical disease agents including flaviviruses and alphaviruses in clinical diagnostic environments.
Genetic Signatures executive team
- Michael Anton AicherExecutive Chairman & Executive Director of US Operations
- Maria HalaszChief Executive Officer
- Christopher M. AbbottFounder & Chairman Emeritus
- Angela WangFinancial Controller
- Susanne K. PedersenChief Technology Officer
- Rebecca AbbatantuonoChief People Officer
- Sonya Tissera?IsaacsCompany Secretary
Recent announcements
What Genetic Signatures (GSS) has told the market, newest first.
- Quarterly Activities/Appendix 4C Cash Flow ReportPrice sensitive
- Change of Company Secretary
- Change in substantial holding
- Change in substantial holding
Key financials
Reported results for Genetic Signatures, in AUD.
- Market cap
- 17.7M
- Revenue (TTM)
- 19.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- -72.5%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 14.5M | -17.7M | -14M | |
| 15.9M | -18.5M | -20.1M | |
| 9.8M | -22.3M | -17.9M | |
| 16.9M | -18.9M | -14.1M |